A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability

• Published in: Cancer research (Chicago, Ill.) Ill.), 2021-11, Vol.81 (21), p.5438-5450
• Main Authors: Temps, Carolin, Lietha, Daniel, Webb, Emily R, Li, Xue-Feng, Dawson, John C, Muir, Morwenna, Macleod, Kenneth G, Valero, Teresa, Munro, Alison F, Contreras-Montoya, Rafael, Luque-Ortega, Juan R, Fraser, Craig, Beetham, Henry, Schoenherr, Christina, Lopalco, Maria, Arends, Mark J, Frame, Margaret C, Qian, Bin-Zhi, Brunton, Valerie G, Carragher, Neil O, Unciti-Broceta, Asier
• Format: Article
• Language: English
• Subjects: Animals; Apoptosis; Bone Neoplasms - drug therapy; Bone Neoplasms - metabolism; Bone Neoplasms - secondary; Breast Neoplasms - drug therapy; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Cell Proliferation; Female; Focal Adhesion Kinase 1 - antagonists & inhibitors; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Piperidines - pharmacology; Protein Conformation; Protein Kinase Inhibitors - pharmacology; Proto-Oncogene Proteins c-abl - antagonists & inhibitors; Pyrazoles - pharmacology; Pyrimidines - pharmacology; Small Molecule Libraries - pharmacology; src-Family Kinases - antagonists & inhibitors; src-Family Kinases - chemistry; src-Family Kinases - metabolism; Tumor Cells, Cultured; Xenograft Model Antitumor Assays
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/0008-5472.CAN-21-0613

Despite the approval of several multikinase inhibitors that target SRC and the overwhelming evidence of the role of SRC in the progression and resistance mechanisms of many solid malignancies, inhibition of its kinase activity has thus far failed to improve patient outcomes. Here we report the small molecule eCF506 locks SRC in its native inactive conformation, thereby inhibiting both enzymatic and scaffolding functions that prevent phosphorylation and complex formation with its partner FAK. This mechanism of action resulted in highly potent and selective pathway inhibition in culture and . Treatment with eCF506 resulted in increased antitumor efficacy and tolerability in syngeneic murine cancer models, demonstrating significant therapeutic advantages over existing SRC/ABL inhibitors. Therefore, this mode of inhibiting SRC could lead to improved treatment of SRC-associated disorders. SIGNIFICANCE: Small molecule-mediated inhibition of SRC impairing both catalytic and scaffolding functions confers increased anticancer properties and tolerability compared with other SRC/ABL inhibitors.